## LLY: Eli Lilly and Company - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -1.7% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($950.58)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 10, Bearish: 0)

**1. Roll Tide: Lilly selects Alabama site as location for $6B API facility**
- Source: Fierce Pharma | 20251209T200907 | Bullish | Relevance: 99%
-  Eli Lilly announced Huntsville, Alabama, as the location for a $6 billion active pharmaceutical ingredient (API) manufacturing facility, the third of four planned "mega sites" in the U.S. This plant will produce API for peptide and small-molecule medicines, including the GLP-1 weight-loss pill orforglipron, and is expected to create 450 jobs. The investment is part of a larger $27 billion plan to bolster domestic manufacturing and supply chain resilience.

**2. Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial | Eli Lilly and Company**
- Source: Eli Lilly and Company | 20251211T120833 | Bullish | Relevance: 99%
-  Eli Lilly and Company announced positive topline results from the Phase 3 TRIUMPH-4 clinical trial for retatrutide, a triple hormone receptor agonist, showing significant weight loss and improvements in knee osteoarthritis pain and physical function. Participants treated with retatrutide lost an average of up to 28.7% (71.2 lbs) of body weight and experienced up to a 75.8% reduction in WOMAC pain scores. These results highlight retatrutide's potential as an important option for patients with obesity and complications like knee osteoarthritis, with additional Phase 3 readouts expected in 2026.

**3. Lilly to build $6 billion facility to manufacture active pharmaceutical ingredients in Alabama**
- Source: PR Newswire | 20251210T170838 | Bullish | Relevance: 99%
-  Eli Lilly and Company announced a $6 billion investment to build a new manufacturing facility in Huntsville, Alabama, focusing on active pharmaceutical ingredients for small molecule synthetic and peptide medicines, including orforglipron. This investment will create 450 jobs and an additional 3,000 construction jobs, strengthening Lilly's U.S. domestic manufacturing capacity and supply chain resilience. The Huntsville site was chosen due to its skilled workforce, advanced manufacturing expertise, and proximity to the HudsonAlpha Institute for Biotechnology.

**4. Carolyn Bertozzi Returns to Eli Lilly and Company Board of Directors 2025**
- Source: Oncodaily | 20251209T110822 | Bullish | Relevance: 98%
-  Eli Lilly and Company announced the re-election of Nobel laureate Carolyn R. Bertozzi, Ph.D., to its Board of Directors, effective December 8, 2025. Dr. Bertozzi, known for her pioneering work in bioorthogonal chemistry, will serve on the Science and Technology Committee and the Ethics and Compliance Committee. Her return is expected to reinforce Lilly's commitment to scientific excellence and ethical leadership, leveraging her insights in targeted medicine and drug development.

**5. Eli Lilly to build $6 billion Alabama plant as part of US manufacturing push**
- Source: Reuters | 20251210T150824 | Bullish | Relevance: 98%
-  Eli Lilly announced plans to invest over $6 billion in a new active drug ingredient manufacturing facility in Huntsville, Alabama. This investment, the third new U.S. facility for Lilly, aims to expand domestic production and strengthen medicine supply chains, particularly for drugs like its oral GLP-1 weight-loss drug. Construction is set to begin in 2026, creating 3,000 construction jobs and 450 permanent roles, with completion targeted for 2032.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 8, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-10 | Wells Fargo | $1200 | $1100 | +9% |
| 2025-12-04 | BMO Capital | $1200 | $1100 | +9% |
| 2025-11-24 | Morgan Stanley | $1290 | $1171 | +10% |
| 2025-11-24 | Bernstein | $1300 | $1100 | +18% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-10 | Wells Fargo | main | Overweight |
| 2025-12-04 | BMO Capital | main | Outperform |
| 2025-11-24 | Morgan Stanley | main | Overweight |
| 2025-11-24 | Bernstein | main | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 20 ($2.11M) |
| Sells | 30 ($207.96M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 45.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Lilly Endowment, Inc: 10.1% (-0.5%)
- Vanguard Group Inc: 8.6% (+0.7%)
- Blackrock Inc.: 7.0% (-0.2%)
- PNC Financial Servic: 5.4% (+0.1%)
- State Street Corpora: 3.7% (+0.6%)

### Key Risks

1. Heavy insider selling: $208M sold (30 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 8 raises (avg +12%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 0.90 indicates undervaluation relative to growth. Forward P/E 31.2x attractive for 37% earnings growth. Quality metrics strong (ROE 96%, ROA 18%, margin 31%). Balance sheet: $8.6B free cash flow. Analyst sentiment positive (8 raises, avg +12%). Insider selling cluster ($208.0M in 90 days), potential headwind. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $904.9B |
| Beta | 0.37 |
| 52W Range | $623.78 - $1111.99 |
| Short Interest | 0.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.90 |
| Forward P/E | 31.2 |
| Current P/E | 42.6 |
| YoY Growth | 36.9% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -6.1% to -1.7% (+4.5% in 5 days), confirming momentum buildup. Below STRENGTH zone by 4.7pp (needs >3.0% for momentum thesis). MRS_5 turning positive (1.1%) - potential reversal signal. Long-term uptrend intact (above SMA200 at 1.24x) but short-term weakness (below SMA20). MACD histogram bearish (-15.51), momentum weakening. RSI neutral at 54.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.66% (CS: 20) | Neutral |
| RSI_14 | 53.7 | Neutral |
| MACD Histogram | -15.51 | Bearish |
| vs SMA20 | 0.973x | Below |
| vs SMA50 | 1.085x | Above |
| vs SMA200 | 1.240x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $1009.38
- **Stop Loss:** $950.58 (5.8% risk)
- **Target:** $1068.18 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 23
- **Position Value:** $23,215.74
- **Portfolio %:** 23.22%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-02-05 (Est: $7.18)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.89 | $7.02 | +19.1% |
| 2025Q2 | $5.59 | $6.31 | +12.9% |
| 2025Q1 | $3.54 | $3.34 | -5.7% |
| 2024Q4 | $5.07 | $5.32 | +5.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*